JoaquinLSorry to see you go JL...
I think you have had a pretty balanced view. I do however think you left early, esecially considering you have gone through so much pain to get to this point. As far as I see it, we have a free ride through 1402 Phase II results, CE Mark, Hemosol resolution (which still could realistically bring a strong partner on board) UK IPO and potential PRDT Filter purchase agreements.
To me, the short term on this story has never looked better from a risk reward standpoint (although I admit that isnt saying much) I agree with you that 1402 has become much more important to the company than it was before, but I think you are downplaying the importance of the fractionation technology.
Anyway, we'll see... I hope your wrong and wish you the best